Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Alcohol Use Disorder

Alcohol Use Disorder

Subtypes of Alcohol Use Disorder

Alcohol dependence 0

13 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Alcohol Use Disorder

144 trials tracked for Alcohol Use Disorder: 14 in phase 3 or 4 and 4 with published results. The most-cited published study has 61 citations.

144Trials tracked
14Phase 3 & 4
0Recruiting
4With published results
Phase distribution
Phase 4 9 Phase 3 5 Phase 2 49 Phase 1 13 Other / NA 68
  1. Phase 3 Comparing Treatments for HIV-Infected Opioid and Alcohol Users in an Integrated Care Effectiveness Study Completed · 61 cited
  2. Phase 4 Alcohol Disorder hOsPital Treatment Trial Completed · 18 cited
  3. Phase 4 Neural Mechanisms of Disulfiram Effects Completed · 12 cited
  4. Phase 3 Pharmacogenetic Treatment With Anti-Glutaminergic Agents for Comorbid PTSD & AUD Completed · 4 cited
  5. Phase 4 Serotonin Selective Reuptake Inhibitor Treatment of Dual Diagnosis Post-traumatic Stress Disorder and Alcohol Problems Completed
  6. Phase 4 Paroxetine for Comorbid Social Anxiety Disorder and Alcoholism Completed
Show 44 more trials
  1. Phase 4 Ondansetron for Bipolar Disorder and Alcohol Use Disorders Completed
  2. Phase 4 Extended-release Naltrexone and Care Management for Alcohol Dependent Frequent Emergency Department Users Completed
  3. Phase 4 Clinical Medication Development for Bipolar Disorder and Alcohol Use Disorders Completed
  4. Phase 4 Pharmacogenomics and Pharmacometabolomics of Acamprosate Treatment Outcome Completed
  5. Phase 4 Alcohol Research Consortium in HIV-Intervention Research Arm Completed
  6. Phase 3 Zonisamide Treatment of Alcohol Use Disorder: an Evaluation of Efficacy and Mechanism of Action Completed
  7. Phase 3 Dutasteride Treatment for Reducing Heavy Drinking in AUD: Predictors of Efficacy Completed
  8. Phase 3 Lemborexant Augmentation of Naltrexone for Alcohol Craving and Sleep Completed
  9. Phase 2 Effect of Endotoxin on Alcohol Consumption Completed
  10. Phase 2 PPARγ Agonist Treatment for Cocaine Dependence Completed
  11. Phase 2 Cannabidiol as a Treatment for AUD Comorbid With PTSD Completed
  12. Phase 2 Manipulating Ghrelin Signaling Via GOAT Inhibition in Alcohol Use Disorder Completed
  13. Phase 2 Semaglutide for Alcohol Use Disorder Completed
  14. Phase 2 Modafinil for the Treatment of Alcohol Use Disorders Completed
  15. Phase 2 Enhancing the Effects of Alcohol Treatment With Lamotrigine Completed
  16. Phase 2 HORIZANT (Gabapentin Enacarbil Extended-Release Tablets) for the Treatment of Alcohol Use Disorder Completed
  17. Phase 2 Oxytocin, Alcohol Craving, and Intimate Partner Aggression Completed
  18. Phase 2 Human Laboratory Study of ASP8062 for Alcohol Use Disorder Completed
  19. Phase 2 A Novel Human Lab Model for Screening AUD Medications Completed
  20. Phase 2 Naltrexone for Individuals of East Asian Descent Completed
  21. Phase 2 Medication Development for Protracted Abstinence in Alcoholism: CORT118335 Versus Placebo Completed
  22. Phase 2 N-Acetylcysteine for Adolescent Alcohol Use Disorder Completed
  23. Phase 2 Pregabalin as Treatment for Alcohol Use Disorder Completed
  24. Phase 2 Gabapentin for Alcohol Relapse Prevention Completed
  25. Phase 2 Medication Development in Alcoholism: Apremilast Versus Placebo Completed
  26. Phase 2 Ibudilast and Withdrawal-Related Dysphoria Completed
  27. Phase 2 Effects of Cannabidiol in Alcohol Use Disorder Completed
  28. Phase 2 Pilot Human Lab Study of Lacosamide in Alcohol Use Disorder (AUD) Completed
  29. Phase 2 Combining Varenicline and Naltrexone for Smoking Cessation Completed
  30. Phase 2 Intranasal Oxytocin for the Treatment of Alcohol Use Disorder Completed
  31. Phase 2 A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder Completed
  32. Phase 2 Harm Reduction With Pharmacotherapy (HaRP) Completed
  33. Phase 2 Human Laboratory Study of Varenicline for Alcohol Use Disorder Completed
  34. Phase 2 INIA Stress and Chronic Alcohol Interactions: Glucocorticoid Antagonists in Heavy Drinkers Completed
  35. Phase 2 Ibudilast for the Treatment of Alcohol Use Disorder Completed
  36. Phase 2 Prazosin and Naltrexone (PaN) Study for Veterans With Alcohol Use Disorders Completed
  37. Phase 2 Oxytocin Suppresses Substance Use Disorders Associated With Chronic Stress Completed
  38. Phase 2 Development of Ivermectin for Alcohol Use Disorders Completed
  39. Phase 2 Examining Alcohol Consumption, Perceptions, and User Experience of Alcohol Moderation Strategies Completed
  40. Phase 2 Effects of Pioglitazone on Stress Reactivity and Alcohol Craving Completed
  41. Phase 2 Effects of Cortical Dopamine Regulation on Drinking, Craving, and Cognitive Control Completed
  42. Phase 2 Oxytocin and Stress Response in Alcohol Use Disorder Completed
  43. Phase 2 Medication Development for Opioid and Alcohol Abuse Completed
  44. Phase 2 St. PETERsburg Pain and Alcohol Intervention With Naltrexone and Nalmefene Completed

Showing the 50 most-cited and recently-updated of 144 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Alcohol Use Disorder: what the trials found

Pharmacological interventions for Alcohol Use Disorder include several established options. Oral naltrexone (PO-NTX) demonstrated a reduction in heavy drinking days by -46.4% and -38.4% over 3 months 12. Extended-release naltrexone was also evaluated, with results showing specific metrics for treatment initiation, retention on pharmacotherapy, and HIV viral suppression 21.

Other established pharmacological agents include disulfiram 13, acamprosate, which showed a mean of 81 to 82.5 days until first heavy relapse 15, and ondansetron 18. Additionally, extended-release naltrexone combined with care management (XR-NTX+CM) was associated with lower heavy drinking days and higher quality of life scores compared to a control group 17.

Counseling for alcohol pharmacotherapy resulted in a reduction in Audit-C scores 14. Other agents investigated include lemborexant 1, paroxetine 19, and sertraline, the latter of which showed no significant difference in heavy drinking days or PTSD symptom scores compared to its comparator 20.

A combination of pregabalin plus BBCET was evaluated; however, it did not show statistically significant differences in heavy drinking days or PTSD cluster symptoms 22.

Recent results — preliminary, needs further review

  • BPL-003 showed no clinically significant abnormal laboratory tests (0%) or vital signs (4%) among participants 2.
  • Standardized kudzu was evaluated for its impact on binge drinking days 3.
  • Gamified Personalized Normative Feedback did not show statistically significant changes in daily drinking at 4, 9, or 12 months 5.
  • Active rTMS showed a borderline significant result for the number of participants who abstained from alcohol (p=0.05), but no significant differences were found in glutamate concentration or cortical volume 10.
  • Behavioral Activation (BA) did not show statistically significant changes in alcohol use, PTSD severity, or psychosocial functioning 7.

For the clinician treating this condition

  • Oral naltrexone and extended-release naltrexone (with or without care management) are established options for reducing heavy drinking days.
  • Acamprosate and disulfiram are established pharmacological interventions for managing alcohol use.
  • Counseling specifically regarding pharmacotherapy is associated with improved Audit-C scores.

AI synthesis of 16 cited trials, updated Jun 23, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
HCV treatment with direct-acting antivirals linked to reduced alcohol use in people who inject drugs
Gastroenterology RCT
HCV treatment with direct-acting antivirals linked to reduced alcohol use in people who inject drugs HCV treatment linked to reduced alcohol use in people who inject drugs
A secondary analysis of a pragmatic RCT in 755 people who inject drugs (PWID) found that achieving sustained virological response (SVR) was …
People who inject drugs and cured of hepatitis C showed lower alcohol use scores at every follow-up visit compared to their baseline.
Apr 2, 2026

Questions about Alcohol Use Disorder

What is the impact of excessive alcohol use on years of life lost in the US population?

Excessive alcohol use causes about 178,000 deaths and 2.8 million years of potential life lost annually in the US, with rates increasing in recent years.

Full answer →